This standard covers antifungal agent selection and preparation, test procedure implementation and interpretation, and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

Barbara D. Alexander, MD, MHS
Gary W. Procop, MD, MS
Philippe Dufresne, PhD (RMCCM)
Jeff Fuller, PhD, FCCM, D(ABMM)
Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
Kimberly E. Hanson, MD, MHS
Denise Holliday, MT(ASCP)
Nicole M. Holliday, BA
Laura Kovanda, PhD
Shawn R. Lockhart, PhD, D(ABMM)
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute standard M27—Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts describes a method for testing the susceptibility to antifungal agents of yeasts that cause invasive fungal infections, including Candida spp. and Cryptococcus neoformans. Selection and preparation of antifungal agents, implementation and interpretation of test procedures, and the purpose and implementation of QC procedures are discussed. A careful examination of the responsibilities of the manufacturer and the user in QC is also presented.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2017 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation


Previous Editions:
Contents

Abstract.................................................................................................................................................... i
Committee Membership........................................................................................................................ iii
Foreword.............................................................................................................................................. vii

Chapter 1: Introduction ....................................................................................................................... 1
1.1 Scope........................................................................................................................................... 1
1.2 Background ............................................................................................................................... 1
1.3 Standard Precautions ............................................................................................................. 2
1.4 Terminology ............................................................................................................................. 2

Chapter 2: Preparing for Antifungal Susceptibility Testing ............................................................... 5
2.1 Indications for Performing Antifungal Susceptibility Tests .................................................... 5
2.2 Selecting Antifungal Agents for Routine Testing and Reporting ........................................ 6

Chapter 3: Antifungal Broth Dilution Susceptibility Testing Process for Yeasts ............................... 7
3.1 Preparing Antifungal Agents ................................................................................................ 9
3.2 Testing Procedures .............................................................................................................. 11
3.3 Reading Minimal Inhibitory Concentration Results ....................................................... 15
3.4 Interpreting Results .......................................................................................................... 17

Chapter 4: Quality System Essential: Process Management – Quality Control ............................... 19
4.1 Quality Control Purpose ..................................................................................................... 19
4.2 Quality Control Responsibilities ......................................................................................... 19
4.3 Selecting Reference Strains ............................................................................................. 20
4.4 Storing Reference Strains ................................................................................................. 20
4.5 Controlling Media Batches and Plasticware Lots ............................................................. 22
4.6 Quality Control Frequency ............................................................................................... 22
4.7 Other Quality Control Procedures .................................................................................... 23

Chapter 5: Conclusion ....................................................................................................................... 24

Chapter 6: Supplemental Information ............................................................................................. 24

References......................................................................................................................................... 25

Appendix A. Preparing Dilution Series of Water-Insoluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests ........................................................................................................... 27
Appendix B. Composition of Roswell Park Memorial Institute 1640 Culture Medium (With Glutamine and Phenol Red but Without Bicarbonate) ................................................................. 28
Appendix C. Preparing Roswell Park Memorial Institute 1640 Culture Medium .................................................. 29
Appendix D. Preparing Dilution Series of Water-Soluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests ........................................................................................................... 30
Appendix E. 0.5 McFarland Barium Sulfate Turbidity Standard .................................................. 31
The Quality Management System Approach .................................................................................... 32
Related CLSI Reference Materials ................................................................................................. 33
Foreword

With the increased incidence of systemic fungal infections and the growing number of available antifungal agents, laboratory guidance for selecting antifungal therapy has gained greater attention. In 1982, the CLSI Area Committee for Microbiology formed the Subcommittee on Antifungal Susceptibility Tests. In 1985, this subcommittee published its first report, in which the results of a questionnaire and a small collaborative study were presented. Based on these findings, the subcommittee concluded that it would be useful to work toward a more reproducible reference testing procedure.

Agreement already existed regarding several elements of the procedure. For example, to facilitate additional analysis of various test conditions, it was agreed that the reference method should be a broth dilution procedure. Because of examples of drug antagonism by some complex media for certain antifungal agents, the subcommittee restricted its interest to fully defined synthetic media only. Drug stock solution preparation and dilution procedures previously developed for antibacterial testing procedures were adopted with minor modifications. Despite agreement in some areas, for other factors, additional data needed to be resolved, including:

- Inoculum preparation
- Inoculum size
- Choice among several synthetic media
- Incubation temperature
- Incubation duration
- End-point definition

These factors were the focus of a series of collaborative studies.\(^1\)\(^-\)\(^4\) As a result, the subcommittee reached agreement on all factors, which led to the publication of M27-P in 1992. In the next four years, reference minimal inhibitory concentration (MIC) ranges were established for two QC strains for the available antifungal agents,\(^5\)\(^,\)\(^6\) and broth microdilution procedures paralleling the broth macrodilution reference procedure became available.\(^4\)\(^-\)\(^9\) This information was included in a revised standard in 1995 (M27-T). In revising the standard, the subcommittee focused its attention on developing relevant breakpoints for available antifungal agents,\(^10\) included in M27-A in 1997. Since then, the subcommittee has developed 24- and 48-hour reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.\(^11\) The study results are included in this standard and CLSI document M60.\(^12\)

Overview of Changes

This standard replaces the previous edition of the approved standard, M27-A3, published in 2008. Several changes were made in this edition, including:

- **General:**
  - Revised document format and organization to reflect the CLSI quality system essential and path of workflow document templates and the updated CLSI style
  - Updated references to the previous informational supplements (M27-S4 and M44-S3) to reflect CLSI document M60,\(^12\) the new supplement for broth dilution and disk diffusion yeast susceptibility testing
  - Added references to epidemiological cutoff values and CLSI documents M57\(^13\) and M59\(^14\)
• **Subchapter 1.4.2, Definitions:**
  – Revised the breakpoint and interpretive category definitions for consistency with other CLSI antimicrobial susceptibility testing documents
  – Added definitions for “wild-type” and “non-wild-type”
  – Deleted all uses of the phrase “interpretive criteria”

• **Chapter 3, Antifungal Susceptibility Testing Process:**
  – Added an antifungal susceptibility testing process flow chart
  – Replaced procedural text with step-action tables
  – Added an explanation for deleting breakpoints for itraconazole and flucytosine
  – Changed recommended reading time for broth microdilution to 24 hours only for clinical isolates and QC strains (24 and/or 48 hours was accepted for some antifungal agents in M27-A3)
  – Deleted results interpretation information for ketoconazole

**NOTE:** The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

**Key Words**

Antifungal agent, broth macrodilution, broth microdilution, susceptibility testing, yeasts
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

Chapter 1: Introduction

This chapter includes:

- Standard’s scope and applicable exclusions
- Background information pertinent to the standard’s content
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

1.1 Scope

This standard describes a reference method for testing susceptibility to antifungal agents of yeasts that cause infections, including Candida spp. and Cryptococcus spp. The intended users are laboratory personnel who perform antifungal susceptibility testing on yeasts. The focus is on developing relevant breakpoints for available antifungal agents and reference minimal inhibitory concentration (MIC) ranges for broth dilution testing of both established and newly introduced antifungal agents. For MIC breakpoints, interpretive categories, and MIC ranges for QC isolates, refer to CLSI document M60. This method has not been extensively validated for the yeast forms of dimorphic fungi, such as Blastomyces dermatitidis or Histoplasma capsulatum. Also, testing filamentous fungi (moulds) introduces several additional standardization problems not covered by this procedure and is not included. For an antifungal broth dilution susceptibility testing reference method for filamentous fungi, refer to CLSI document M38.

Commercially available susceptibility test systems are out of scope for this standard. It is recommended that users of these systems refer to the manufacturer’s instructions as outlined in the package insert.

1.2 Background

This standard provides a reference method developed through a consensus process to facilitate agreement among laboratories in measuring yeast susceptibility to antifungal agents. An important use of a reference method is to provide a standard basis from which other methods can be developed, which also results in interlaboratory agreement within specified ranges. For example, broth microdilution methods using an indicator dye to facilitate breakpoint determinations have been configured to produce results paralleling those obtained by the broth microdilution reference method. To the extent that any method produces results concordant with this reference method, it would be considered to conform with this standard.
1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory. 

For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.

1.4 Terminology

1.4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in different countries and regions and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. CLSI recognizes its important role in these efforts, and its consensus process focuses on harmonization of terms to facilitate the global application of standards and guidelines.

NOTE: Current fungal taxonomy is being revised. Many genera have both a teleomorph (sexual state) and an anamorph (asexual state) name. In this standard, the traditional Candida spp. and Cryptococcus spp. names are used to provide continuity to both past procedures and associated documents such as CLSI document M60.

1.4.2 Definitions

antibiogram – overall profile of antimicrobial susceptibility testing results of a microbial species to a battery of antimicrobial agents.

breakpoint – minimal inhibitory concentration (MIC) or zone diameter value used to categorize an organism as susceptible, susceptible-dose dependent, intermediate, or resistant; NOTE 1: MIC or zone diameter values generated by a susceptibility test can be interpreted based upon established breakpoints; NOTE 2: See interpretive category.

epidemiological cutoff value (ECV) – the minimal inhibitory concentration (MIC) or zone diameter value that separates microbial populations into those with and without acquired and/or mutational resistance based on their phenotypes (wild-type or non-wild-type). The ECV defines the upper limit of susceptibility for the wild-type population of isolates.

EXAMPLE:

<table>
<thead>
<tr>
<th>Interpretive Category</th>
<th>MIC, µg/mL</th>
<th>ECVs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type</td>
<td>≤4</td>
<td>≥20</td>
</tr>
<tr>
<td>Non-wild-type</td>
<td>≥8</td>
<td>≤19</td>
</tr>
</tbody>
</table>
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system (QMS) approach in the development of standards and guidelines that facilitates project management, defines a document structure using a template, and provides a process to identify needed documents. The QMS approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (i.e., operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Organization
- Customer Focus
- Personnel
- Purchasing and Inventory
- Process Management
- Documents and Records
- Facilities and Safety
- Equipment
- Management
- Information Management
- Nonconforming Event Management
- Assessments
- Continual Improvement

M27 covers the QSE indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Customer Focus</th>
<th>Personnel</th>
<th>Purchasing and Inventory</th>
<th>Process Management</th>
<th>Documents and Records</th>
<th>Facilities and Safety</th>
<th>Equipment</th>
<th>Management</th>
<th>Information Management</th>
<th>Nonconforming Event Management</th>
<th>Assessments</th>
<th>Continual Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M27</td>
<td>M29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver their services, namely quality laboratory information.

M27 covers the medical laboratory path of workflow processes indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.

<table>
<thead>
<tr>
<th>Preexamination</th>
<th>Examination</th>
<th>Postexamination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination ordering</td>
<td>Sample collection</td>
<td>Sample transport</td>
</tr>
<tr>
<td>X</td>
<td>M38</td>
<td>M59</td>
</tr>
</tbody>
</table>
Related CLSI Reference Materials*

M23  Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters. 4th ed., 2016. This guideline discusses the necessary and recommended data for selecting appropriate breakpoints and quality control ranges for antimicrobial agents.

M29  Protection of Laboratory Workers From Occupationally Acquired Infections. 4th ed., 2014. Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

M38  Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. 3rd ed., 2017. This standard includes antifungal agent selection, preparation of antifungal stock solutions and dilutions for testing, test procedure implementation and interpretation, and quality control requirements for susceptibility testing of filamentous fungi (moulds) that cause invasive and cutaneous fungal infections.

M57  Principles and Procedures for the Development of Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed., 2016. This guideline includes the criteria for developing and using epidemiological cutoff values for guiding clinical decisions when testing fungal species and antifungal agent combinations for which there are no breakpoints.

M59  Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed., 2016. This document includes the epidemiological cutoff value and quality control tables developed according to criteria provided in the Clinical and Laboratory Standards Institute guideline M57.

M60  Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st ed., 2017. This document includes updated minimal inhibitory concentration, zone diameter, and quality control tables for the Clinical and Laboratory Standards Institute antifungal susceptibility testing documents M27 and M44.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI's efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.